Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing Arthroplasty

20260 citationsJournal Articlehybrid Open Access

Authors

An Tran-Duy · Melbourne Health

Sarah Asbury · Melbourne Health

Tim Spelman · Burnet Institute

David L. Paterson · National University of Singapore

Kirsty Buising · The Royal Melbourne Hospital

Catherine McDougall · Prince Charles Hospital

Michael Solomon ·

Abstract

Adding vancomycin to cephazolin prophylaxis in arthroplasty is most likely not cost-effective. Omitting vancomycin could lead to substantial annual savings for the healthcare sector without compromising health outcomes.

Topics & Keywords

Orthopedic Infections and Treatments Antimicrobial Resistance in Staphylococcus Surgical site infection prevention

UN Sustainable Development Goals

Zero hungerDecent work and economic growth

Publication Details

Published in: PharmacoEconomics

DOI: 10.1007/s40273-026-01609-0

Field-Weighted Citation Impact: 0.00